All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsUNIVERSITY OF PITTSBURGH AT PITTSBURGH

UNIVERSITY OF PITTSBURGH AT PITTSBURGH

Projects attributed to UNIVERSITY OF PITTSBURGH AT PITTSBURGH within this analysis sample.

In This Analysis
Projects
3
NIH Funding
$2.5M
Projects(3)
ProjectPICategoryFunding
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
5R01CA275766-03
PATEL, RAVI BHASKERTherapeutics$1.2M
Targeting androgen receptor nuclear localization in prostate cancer
5R01CA265897-04
WANG, ZHOUBasic Research$730K
Alpha-Particle Emitter Radiopharmaceutical Therapy for Liver Cancer
R01CA239041
NEDROW, JESSIE (contact)Therapeutics$574K
See UNIVERSITY OF PITTSBURGH AT PITTSBURGH’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.